This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	Claudin 3 (CLDN3)	<p>Studies in mice suggest that small interfering RNA silencing of CLDN3 may help treat ovarian cancer. In three different mouse models of ovarian cancer, lipid-based formulations of CLDN3 siRNA resulted in smaller tumors, tumor regression and increased survival compared with what was seen in untreated controls. Ongoing preclinical work is exploring the use of the CLDN3 siRNA in combination therapies to treat ovarian cancer. Ten companies have therapies that are marketed or approved to treat ovarian cancer.</p> <p>SciBX 2(7); doi:10.1038/scibx.2009.271 Published online Feb. 19, 2009</p>	Patented; licensing status undisclosed	<p>Huang, Y.-H. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 9, 2009; doi:10.1073/pnas.0813348106 Contact: Janet A. Sawicki, Alnylam Pharmaceuticals Inc., Cambridge, Mass. e-mail: sawickij@mlhs.org Contact: Daniel G. Anderson, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: dgander@mit.edu</p>